YC-1 attenuates homotypic human neutrophil aggregation through inhibition of phosphodiesterase activity

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 395-402

  Hwang, Tsong Long ^a   Zhuo, Shi Kai ^a   Pan, Yen Lin ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Aggregation; cAMP; Neutrophil; PDE; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ADENOSINE DEAMINASE; ADENYLATE CYCLASE; COMPLEMENT COMPONENT C5A; CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; MILRINONE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE; ROLIPRAM;

ADULT; ARTICLE; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME INACTIVATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKOCYTE AGGREGATION; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENOSINE; ADULT; CELL AGGREGATION; COMPLEMENT C5A; CYCLIC AMP; ENZYME ACTIVATORS; HUMANS; INDAZOLES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 37549034718     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.022     Document Type: Article

References (47)

1. Ahluwalia A., Foster P., Scotland R.S., McLean P.G., Mathur A., Perretti M., Moncada S., and Hobbs A.J. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1386-1391
2. Bessler H., Gilgal R., Djaldetti M., and Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J. Leukoc. Biol. 40 (1986) 747-754
3. Boyum A., Lovhaug D., Tresland L., and Nordlie E.M. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34 (1991) 697-712
4. Browning D.D., Windes N.D., and Ye R.D. Activation of p38 mitogen-activated protein kinase by lipopolysaccharide in human neutrophils requires nitric oxide-dependent cGMP accumulation. J. Biol. Chem. 274 (1999) 537-542
5. Brunetti M., Mascetra N., Manarini S., Martelli N., Cerletti C., Musiani P., Aiello F.B., and Evangelista V. Inhibition of cGMP-dependent protein kinases potently decreases neutrophil spontaneous apoptosis. Biochem. Biophys. Res. Commun. 297 (2002) 498-501
6. Chang L.C., Wang C.J., Lin Y.L., and Wang J.P. Expression of adenylyl cyclase isoforms in neutrophils. Biochim. Biophys. Acta 1640 (2003) 53-60
7. Coffey R.G. Effects of cyclic nucleotides on granulocytes. Immunol. Ser. 57 (1992) 301-338
8. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76 (1994) 5-13
9. Dallegri F., and Ottonello L. Tissue injury in neutrophilic inflammation. Inflamm. Res. 46 (1997) 382-391
10. Derian C.K., Santulli R.J., Rao P.E., Solomon H.F., and Barrett J.A. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154 (1995) 308-317
11. Ernens I., Rouy D., Velot E., Devaux Y., and Wagner D.R. Adenosine inhibits matrix metalloproteinase-9 secretion by neutrophils. Implication of A2A receptor and cAMP/PKA/Ca2+ pathway. Circ. Res. 99 (2006) 590-597
12. Ferrero R., and Torres M. Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism. Neuropharmacology 41 (2001) 895-906
13. Flamand N., Boudreault S., Picard S., Austin M., Surette M.E., Plante H., Krump E., Vallee M.J., Gilbert C., Naccache P., Laviolette M., and Borgeat P. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am. J. Respir. Crit. Care Med. 161 (2000) S88-S94
14. Forslund T., Nilsson H.M., and Sundqvist T. Nitric oxide regulates the aggregation of stimulated human neutrophils. Biochem. Biophys. Res. Commun. 274 (2000) 482-487
15. Friebe A., Mullershausen F., Smolenski A., Walter U., Schultz G., and Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 54 (1998) 962-967
16. Friebe A., Schultz G., and Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 15 (1996) 6863-6868
17. Gaboury J., Woodman R.C., Granger D.N., Reinhardt P., and Kubes P. Nitric oxide prevents leukocyte adherence: role of superoxide. Am. J. Physiol. 265 (1993) H862-H867
18. Galle J., Zabel U., Hübner U., Hatzelmann A., Wagner B., Wanner C., and Schmidt H.H.H.W. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 127 (1999) 195-203
19. Harada N., Okajima K., Murakami K., Usune S., Sato C., Ohshima K., and Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J. Pharmacol. Exp. Ther. 294 (2000) 1034-1042
20. Harvath L., Robbins J.D., Russell A.A., and Seamon K.B. cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic responsiveness. J. Immunol. 146 (1991) 224-232
21. Hobbs A.J., and Moncada S. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vascul. Pharmacol. 40 (2003) 149-154
22. Hwang T.L., Hung H.W., Kao S.H., Teng C.M., Wu C.C., and Cheng S.J. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol. Pharmacol. 64 (2003) 1419-1427
23. Hwang T.L., Yeh S.H., Leu Y.L., Chern C.Y., and Hsu H.C. Inhibition of superoxide anion and elastase release in human neutrophils by 3′-isopropoxychalcone via a cAMP-dependent pathway. Br. J. Pharmacol. 148 (2006) 78-87
24. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., and Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84 (1994) 4226-4233
25. Kubes P., Suzuki M., and Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 4651-4655
26. Liu Y.N., Pan S.L., Peng C.Y., Guh J.H., Huang D.M., Chang Y.L., Lin C.H., Pai H.C., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J. Pharmacol. Exp. Ther. 316 (2006) 35-41
27. McColl S.R., St-Onge M., Dussault A.A., Laflamme C., Bouchard L., Boulanger J., and Pouliot M. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J. 20 (2006) 187-189
28. Miotla J.M., Teixeira M.M., and Hellewell P.G. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol. 18 (1998) 411-420
29. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide-physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
30. Moro M.A., Russel R.J., Cellek S., Lizasoain I., Su Y., Darley-Usmar V.M., Radomski M.W., and Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1480-1485
31. Mülsch A., Bauersachs J., Schäfer A., Stasch J.P., Kast R., and Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120 (1997) 681-689
32. Ohta A., and Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 (2001) 916-920
33. Ortiz J.L., Dasí F.J., Cortijo J., and Morcillo E.J. beta-Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils. Naunyn-Schmiedeberg's Arch. Pharmacol. 361 (2000) 410-417
34. Pan S.L., Guh J.H., Peng C.Y., Chang Y.L., Cheng F.C., Chang J.H., Kuo S.C., Lee F.Y., and Teng C.M. A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb. Haemost. 93 (2005) 940-948
35. Radomski M.W., Vallance P., Whitley G., Foxwell N., and Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc. Res. 27 (1993) 1380-1382
36. Sato Y. Modulation of PMN-endothelial cells interactions by cyclic nucleotides. Curr. Pharm. Des. 10 (2004) 163-170
37. Thibault N., Burelout C., Harbour D., Borgeat P., Naccache P.H., and Bourgoin S.G. Occupancy of adenosine A2A receptors promotes fMLP-induced cyclic AMP accumulation in human neutrophils: impact on phospholipase D activity and recruitment of small GTPases to membranes. J. Leukoc. Biol. 71 (2002) 367-377
38. Tulis D.A., Durante W., Peyton K.J., Chapman G.B., Evans A.J., and Schafer A.I. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem. Biophys. Res. Commun. 279 (2000) 646-652
39. Underwood D.C., Bochnowicz S., Osborn R.R., Kotzer C.J., Luttmann M.A., Hay D.W., Gorycki P.D., Christensen S.B., and Torphy T.J. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. J. Pharmacol. Exp. Ther. 287 (1998) 988-995
40. van Griensven M., Probst C., Muller K., Hoevel P., and Pape H.C. Leukocyte-endothelial interactions via ICAM-1 are detrimental in polymicrobial sepsis. Shock 25 (2006) 254-259
41. VanUffelen B.E., de Koster B.M., Van den Broek P.J., VanSteveninck J., and Elferink J.G. Modulation of neutrophil migration by exogenous gaseous nitric oxide. J. Leukoc. Biol. 60 (1996) 94-100
42. Wanikiat P., Woodward D.F., and Armstrong R.A. Investigation of the role of nitric oxide and cyclic GMP in both the activation and inhibition of human neutrophils. Br. J. Pharmacol. 122 (1997) 1135-1145
43. Wegener J.W., Gath I., Forstermann U., and Nawrath H. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br. J. Pharmacol. 122 (1997) 1523-1529
44. Wohlfart P., Malinski T., Ruetten H., Schindler U., Linz W., Schoenafinger K., Strobel H., and Wiemer G. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. 128 (1999) 1316-1322
45. Wu C.C., Ko F.N., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 116 (1995) 1973-1978
46. Wu C.C., Ko F.N., and Teng C.M. Inhibition of platelet adhesion to collagen by cGMP-elevating agents. Biochem. Biophys. Res. Commun. 231 (1997) 412-416
47. Yu S.M., Cheng Z.J., Guh J.H., Lee F.Y., and Kuo S.C. Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells. Biochem. J. 306 (1995) 787-792